Meet us at BIO-EUROPE 2021

NextMeeting

Sciomics participates in collaborative clinical trials for the treatment of metaphyseal chondrodysplasia type Schmid (MCDS)

See below for German version

Heidelberg, 12th February, 2018

 

Multinational consortium has been granted 5.7 Million Euro for the development of novel therapeutic approaches in rare skeletal disorders. Sciomics' expertise with the antibody microarray technology herein serves as a valuable tool for biomarker identification and personalized treatment monitoring.

The biotechnology company Sciomics GmbH, located in Heidelberg, Germany, today announced its participation in the multinational clinical project 'MCDS Therapy'. This five-year collaborative study comprises both world-renowned clinical centres as well as small and medium-sized enterprises in the EU and Australia with a total funding of 5.7 Million Euro. In successive clinical trials, the re-purposing of the drug carbamazepine (CBZ) for the treatment of the skeletal disease metaphyseal chondrodysplasia type Schmid (MCDS) will be investigated. Furthermore, 'MCDS Therapy' encompasses biomarker development and health economics assessment studies to deliver an innovative and affordable therapy for MCDS, along with diagnostic and prognostic tools to personalize the treatment.

MCDS is a skeletal disorder resulting in short stature, abnormally shortened or bowed limbs, chronic pain and decreased mobility. Less than 1 in 100,000 people is affected, which renders the disease a so-called orphan disease. The disease is incurable, and MCDS patients rely on the long-term use of pain therapy and usually undergo numerous orthopaedic surgical interventions to correct knee and hip deformities. This burden in pain and disability leads to poor quality of life and extensive healthcare costs.

CBZ received orphan drug designation by the European Commission for the treatment of MCDS in 2016. 'MCDS Therapy' aims at advancing the re-purposing of CBZ to deliver the first non-surgical therapeutic intervention for MCDS. During the course of the project, an assessment of relevant biomarkers will be incorporated. The aim is to discover novel biomarkers that are directly relevant to CBZ treatment of MCDS which can then be used to monitor therapy and are potentially applicable to a broader group of genetic skeletal diseases or human connective tissue disease in general. 'MCDS Therapy' will use a high-content screening approaches to discover panels of potential biomarkers using samples from both mouse models and patient-derived samples. Herein, Sciomics' antibody microarrays serve as a crucial tool to identify and validate biomarkers for diagnosis, prognosis and personalized therapy.

Sciomics GmbH was founded in 2013 as a spin-off company of the German Cancer Research Centre (DKFZ). 'We are glad to participate in this highly innovative project with our solid expertise in antibody microarrays', states Dr. Christoph Schroeder, CEO of Sciomics. 'Accounting for the hallmarks of our microarray technology, which include high throughput, flexibility, multiplex analysis and robustness, I am convinced that our contribution to this novel treatment option for MCDS will be of great service. Especially for the patients suffering from this severe illness.'

> Download press release as PDF-file

 

 

Heidelberg, 12. Februar 2018

Sciomics an klinischen Studien für die Behandlung von Metaphysärer Chondrodysplasie Typ Schmid (MCDS) beteiligt

Multinationales Konsortium mit einem Gesamtbudget von 5,7 Millionen Euro entwickelt neue therapeutische Ansätze für seltene Knochenerkrankungen. Hierbei spielen die Antikörper-Microarrays von Sciomics eine zentrale Rolle bei der Identifizierung von Biomarkern und Personalisierung der Therapie.

Das Biotechnologie-Unternehmen Sciomics GmbH mit Sitz in Heidelberg teilte heute seine Beteiligung an dem multinationalen klinischen Projekt „MCDS Therapy” mit. An dem Kooperationprojekt mit einem Gesamtbudget von 5,7 Millionen Euro über fünf Jahre arbeiten sowohl renommierte klinische Zentren als auch kleinere und mittelständische Unternehmen aus der EU und Australien mit. In mehreren klinischen Studien soll hierbei die Verwendung des Medikamentes Carbamazepin (CBZ) zur Behandlung der Knochenerkrankung Metaphysäre Chondrodysplasie Typ Schmid (MCDS) untersucht werden. Ein wichtiger Teil der Studien ist die Identifizierung und Validierung von Biomarkern für Diagnose, Prognose und personalisierte Therapie sowie gesundheitswirtschaftliche Aspekte, um eine innovative und kostengünstige Therapie für MCDS zu entwickeln.

MCDS ist eine Knochenerkrankung, deren Symptome Kleinwüchsigkeit, verkürzte und gekrümmte Extremitäten, chronische Schmerzen und eine eingeschränkte Beweglichkeit sind. Weniger als eine von 100.000 Personen ist davon betroffen; es handelt sich bei MCDS somit um eine sogenannte „Orphan Disease“. Die Krankheit ist unheilbar; MCDS-Patienten sind somit ihr Leben lang auf Schmerztherapie sowie orthopädische Behandlung angewiesen. Die chronischen Schmerzen und Behinderungen führen bei den Patienten zu einer geringen Lebensqualität und hohen Behandlungskosten.

CBZ hat 2016 die „Orphan Drug Designation“ der Europäischen Kommission für MCDS erhalten. Ziel von „MCDS Therapy“ ist es, mit der Verwendung von CBZ die erste nicht-invasive Therapie für MCDS zu entwickeln.Ein wichtiger Aspekt des Projekts ist die Identifizierung und Validierung von Biomarkern, die eine direkte Relevanz für die CBZ-Behandlung von MCDS haben. Diese könnten für die Therapieüberwachung von MCDS eingesetzt werden und möglicherweise auch auf andere genetisch bedingte Knochen- und Bindegewebserkrankungen übertragen werden. Im Zuge von „MCDS Therapy“ werden sowohl Proben aus Mausmodellen, als auch von MCDS-Patienten untersucht. Hierbei dienen die Antikörper-Microarrays von Sciomics als wichtige Werkzeuge bei der Identifizierung und Validierung von Biomarkern für Diagnose, Prognose und personalisierte Therapie.

Sciomics wurde 2013 als Spin-Off des Deutschen Krebsforschungszentrums (DKFZ) gegründet. „Wir freuen uns sehr, mit unserer langjährigen Microarray-Expertise zu diesem hochinnovativen Projekt beitragen zu können“, sagt Dr. Christoph Schröder, Geschäftsführer der Sciomics GmbH. „Angesichts der Vorteile unserer Antikörper-Microarrays, wie hoher Durchsatz, Flexibilität, hochparallele Analyse und Reproduzierbarkeit, werden wir einen wichtigen Beitrag zu neuen Therapieoptionen für MCDS leisten.”

 

> Pressemitteilung als PDF

 

Sciomics GmbH
Dr. Christoph Schröder
Im Neuenheimer Feld 583
D-69120 Heidelberg
Germany

Phone: +49 (0) 6221 42948-30
Fax : +49 (0) 6221 42948-34
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: https://www.sciomics.de

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Biomarker identification and verification in endometriosis

| 22th Oct 2021 | Scientists at University Medical Centre Ljubljana used our scioDiscover platform for a biomarker identification in endometriosis:

"Discovery proteomics using antibody microarrays that covered 1360 proteins identified 16 proteins with different levels in cases versus the control patients. The validation using an ELISA approach confirmed significant differences in the levels of cartilage oligomeric matrix protein (COMP) and transforming growth factor-β-induced protein ig-h3 (TGFBI) and nonsignificant differences in angiotensinogen (AGT). "

 Janša, V. et al. (2021) ‘Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis’, Scientific Reports, 11:20870. doi: 10.1038/s41598-021-00299-2. 

biomarkers in endometriosis

 

New article | Parkinson's Disease analysed via brain organoids

| Oct 2021 | In a study led by University of Luxembourg and OrganoTherapeutics SARL-S we used our scioPhospho assay to analyse the reaction of a brain organoid model for Parkinson's disease to certain treatments.

Jarazo, J. et al. (2021) ‘Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxy...’, Movement Disorders, in press: doi: 10.1002/mds.28810 (Please get in touch for fulltext).

 

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.

 

Testimonials

Dr. Joachim Lupberger 

Institute for Viral and Liver Disease, Inserm U1110, University of Strasbourg, LabEx HepSYS, Strasbourg, France

"Our lab is focusing on the identification of minimal-invasive biomarkers for liver disease progression. A challenge of our humanized animal models for liver disease is the low volume of blood samples available, which did not pose any problem for the analysis. I was pleased by the prompt, friendly, and uncomplicated contact and was impressed by the results and the thorough report we received. The overall quality was excellent, which made us to continue using the service of Sciomics for follow-up projects analyzing patient material."

Product: scioPhospho

 

 Prof. Dr. Andreas Weigert 

Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany

"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."

Product: scioCD

 

Tweets

  • 30 days ago

    Partner with us at this year's BIO-Europe Digital Partnering Conference by @EBDgroup to learn how we enable precisi… https://t.co/prn3Up4NTH

  • 34 days ago

    RT @ClusterDanish: “Every drug has a number of persons not responding”. Solution? Precision medicine! Right. Time. Patient. Treatment. Dose…

  • 44 days ago

    Don't miss out on Dr. Schmidt's talk at this year's Week of Health and INNovation hosted by Danish Life Science Clu… https://t.co/PlkBD70X2p

  • 92 days ago

    Join our CEO Dr Christoph Schröder @ChristophSch78 at this year's @DxPx_Conference to learn about our new… https://t.co/lMdvKMHC0D

  • 93 days ago

    Take a look at our joint poster presented by our partners at Neurosys at this year's AAIC, depicting new Protein- a… https://t.co/Vkl63pHy1J